Abstract P3-12-09: Factors influencing aromatase inhibitor induced musculoskeletal syndrome: Roles of menopause timing and osteoporosis therapy

Conclusions: The incidence of AIMSS in our review was 41%. Patients treated in the metastatic setting may have a lower rate of AIMSS. Our cohort revealed that more recent menopause did seem to be a risk factor. Baseline osteoporosis and osteoporosis treatments have a potential association to be explored. Management options included switching between AIs, temporary discontinuation, and NSAID treatment. Updated analysis will be presented. canres;75/9_Supplement/P3-12-09/TBL1T1tbl1 Potential risk factors for the development of AIMSS CharacteristicN(-)Arthralgia N(%)(+)Arthralgia N(%)p-value Type of AI Used Anastrozole 204 112(55.9) 92(45.1) 0.19 Letrozole 131 83(63.4) 48(36.6) Exemestane 36 23(64.9) 13(36.1) Menopause timing LMP < 5 years prior to AI start 151 79(52.3) 72(47.7) 0.055 LMP 5-10 years prior to AI start 40 23(57.5) 17(42.5) LMP > 10 years prior to AI start 155 102(65.8) 53(34.2) Type of therapy Adjuvant 348 200(57.5) 148(42.5) 0.067 Metastatic 22 17(77.3) 5(22.7) Baseline T-score by DEXA Scan Normal (T-score 0 to -1.49) 112 55(49.1) 57(50.9) 0.049 Osteopenia (T-score -1.5 to -2.49) 171 96(56.1) 75(43.9) Osteoporosis(T-score < -2.5) 40 29(72.5) 11(27.5) On active osteoporosis therapy† (-) Therapy 218 118(54.1) 100(45.9) 0.03 (+) Therapy 127 81(63.8) 41(32.3) † Bisphosphonate/denosumab; LMP=Last menstrual period, AI=Aromatase Inhibitor, DEXA=Dual-energy x-ray absorptiomotry Citation Format: Clinton R Morgan, Zsolt Kulcsar, Jonathan D Jones, William F Rigby, Peter ...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research